Shares of Mineralys Therapeutics, Inc. (MLYS) have gained 2% over the past four weeks to close the last trading session at $14.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$36.25 indicates a potential upside of 149.7%. The average comprises eight short-term price targets ranging from a low of $15.00 to a high of$48.00, with a standard deviation of $11.25. While the lowes ...